Copyright Reports & Markets. All rights reserved.

Global Hemophilia Gene Therapy Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Hemophilia Gene Therapy by Type
    • 1.3.1 Overview: Global Hemophilia Gene Therapy Market Size by Type: 2020 Versus 2024 Versus 2031
    • 1.3.2 Global Hemophilia Gene Therapy Consumption Value Market Share by Type in 2024
    • 1.3.3 Hemophilia A
    • 1.3.4 Hemophilia B
  • 1.4 Global Hemophilia Gene Therapy Market by Application
    • 1.4.1 Overview: Global Hemophilia Gene Therapy Market Size by Application: 2020 Versus 2024 Versus 2031
    • 1.4.2 Hemophilia A Gene Therapy
    • 1.4.3 Hemophilia B Gene Therapy
  • 1.5 Global Hemophilia Gene Therapy Market Size & Forecast
  • 1.6 Global Hemophilia Gene Therapy Market Size and Forecast by Region
    • 1.6.1 Global Hemophilia Gene Therapy Market Size by Region: 2020 VS 2024 VS 2031
    • 1.6.2 Global Hemophilia Gene Therapy Market Size by Region, (2020-2031)
    • 1.6.3 North America Hemophilia Gene Therapy Market Size and Prospect (2020-2031)
    • 1.6.4 Europe Hemophilia Gene Therapy Market Size and Prospect (2020-2031)
    • 1.6.5 Asia-Pacific Hemophilia Gene Therapy Market Size and Prospect (2020-2031)
    • 1.6.6 South America Hemophilia Gene Therapy Market Size and Prospect (2020-2031)
    • 1.6.7 Middle East & Africa Hemophilia Gene Therapy Market Size and Prospect (2020-2031)

2 Company Profiles

  • 2.1 Spark Therapeutics
    • 2.1.1 Spark Therapeutics Details
    • 2.1.2 Spark Therapeutics Major Business
    • 2.1.3 Spark Therapeutics Hemophilia Gene Therapy Product and Solutions
    • 2.1.4 Spark Therapeutics Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
    • 2.1.5 Spark Therapeutics Recent Developments and Future Plans
  • 2.2 Ultragenyx
    • 2.2.1 Ultragenyx Details
    • 2.2.2 Ultragenyx Major Business
    • 2.2.3 Ultragenyx Hemophilia Gene Therapy Product and Solutions
    • 2.2.4 Ultragenyx Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
    • 2.2.5 Ultragenyx Recent Developments and Future Plans
  • 2.3 Shire PLC
    • 2.3.1 Shire PLC Details
    • 2.3.2 Shire PLC Major Business
    • 2.3.3 Shire PLC Hemophilia Gene Therapy Product and Solutions
    • 2.3.4 Shire PLC Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
    • 2.3.5 Shire PLC Recent Developments and Future Plans
  • 2.4 Sangamo Therapeutics
    • 2.4.1 Sangamo Therapeutics Details
    • 2.4.2 Sangamo Therapeutics Major Business
    • 2.4.3 Sangamo Therapeutics Hemophilia Gene Therapy Product and Solutions
    • 2.4.4 Sangamo Therapeutics Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
    • 2.4.5 Sangamo Therapeutics Recent Developments and Future Plans
  • 2.5 Bioverativ
    • 2.5.1 Bioverativ Details
    • 2.5.2 Bioverativ Major Business
    • 2.5.3 Bioverativ Hemophilia Gene Therapy Product and Solutions
    • 2.5.4 Bioverativ Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
    • 2.5.5 Bioverativ Recent Developments and Future Plans
  • 2.6 BioMarin
    • 2.6.1 BioMarin Details
    • 2.6.2 BioMarin Major Business
    • 2.6.3 BioMarin Hemophilia Gene Therapy Product and Solutions
    • 2.6.4 BioMarin Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
    • 2.6.5 BioMarin Recent Developments and Future Plans
  • 2.7 uniQure
    • 2.7.1 uniQure Details
    • 2.7.2 uniQure Major Business
    • 2.7.3 uniQure Hemophilia Gene Therapy Product and Solutions
    • 2.7.4 uniQure Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
    • 2.7.5 uniQure Recent Developments and Future Plans
  • 2.8 Freeline Therapeutics
    • 2.8.1 Freeline Therapeutics Details
    • 2.8.2 Freeline Therapeutics Major Business
    • 2.8.3 Freeline Therapeutics Hemophilia Gene Therapy Product and Solutions
    • 2.8.4 Freeline Therapeutics Hemophilia Gene Therapy Revenue, Gross Margin and Market Share (2020-2025)
    • 2.8.5 Freeline Therapeutics Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Hemophilia Gene Therapy Revenue and Share by Players (2020-2025)
  • 3.2 Market Share Analysis (2024)
    • 3.2.1 Market Share of Hemophilia Gene Therapy by Company Revenue
    • 3.2.2 Top 3 Hemophilia Gene Therapy Players Market Share in 2024
    • 3.2.3 Top 6 Hemophilia Gene Therapy Players Market Share in 2024
  • 3.3 Hemophilia Gene Therapy Market: Overall Company Footprint Analysis
    • 3.3.1 Hemophilia Gene Therapy Market: Region Footprint
    • 3.3.2 Hemophilia Gene Therapy Market: Company Product Type Footprint
    • 3.3.3 Hemophilia Gene Therapy Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Hemophilia Gene Therapy Consumption Value and Market Share by Type (2020-2025)
  • 4.2 Global Hemophilia Gene Therapy Market Forecast by Type (2026-2031)

5 Market Size Segment by Application

  • 5.1 Global Hemophilia Gene Therapy Consumption Value Market Share by Application (2020-2025)
  • 5.2 Global Hemophilia Gene Therapy Market Forecast by Application (2026-2031)

6 North America

  • 6.1 North America Hemophilia Gene Therapy Consumption Value by Type (2020-2031)
  • 6.2 North America Hemophilia Gene Therapy Market Size by Application (2020-2031)
  • 6.3 North America Hemophilia Gene Therapy Market Size by Country
    • 6.3.1 North America Hemophilia Gene Therapy Consumption Value by Country (2020-2031)
    • 6.3.2 United States Hemophilia Gene Therapy Market Size and Forecast (2020-2031)
    • 6.3.3 Canada Hemophilia Gene Therapy Market Size and Forecast (2020-2031)
    • 6.3.4 Mexico Hemophilia Gene Therapy Market Size and Forecast (2020-2031)

7 Europe

  • 7.1 Europe Hemophilia Gene Therapy Consumption Value by Type (2020-2031)
  • 7.2 Europe Hemophilia Gene Therapy Consumption Value by Application (2020-2031)
  • 7.3 Europe Hemophilia Gene Therapy Market Size by Country
    • 7.3.1 Europe Hemophilia Gene Therapy Consumption Value by Country (2020-2031)
    • 7.3.2 Germany Hemophilia Gene Therapy Market Size and Forecast (2020-2031)
    • 7.3.3 France Hemophilia Gene Therapy Market Size and Forecast (2020-2031)
    • 7.3.4 United Kingdom Hemophilia Gene Therapy Market Size and Forecast (2020-2031)
    • 7.3.5 Russia Hemophilia Gene Therapy Market Size and Forecast (2020-2031)
    • 7.3.6 Italy Hemophilia Gene Therapy Market Size and Forecast (2020-2031)

8 Asia-Pacific

  • 8.1 Asia-Pacific Hemophilia Gene Therapy Consumption Value by Type (2020-2031)
  • 8.2 Asia-Pacific Hemophilia Gene Therapy Consumption Value by Application (2020-2031)
  • 8.3 Asia-Pacific Hemophilia Gene Therapy Market Size by Region
    • 8.3.1 Asia-Pacific Hemophilia Gene Therapy Consumption Value by Region (2020-2031)
    • 8.3.2 China Hemophilia Gene Therapy Market Size and Forecast (2020-2031)
    • 8.3.3 Japan Hemophilia Gene Therapy Market Size and Forecast (2020-2031)
    • 8.3.4 South Korea Hemophilia Gene Therapy Market Size and Forecast (2020-2031)
    • 8.3.5 India Hemophilia Gene Therapy Market Size and Forecast (2020-2031)
    • 8.3.6 Southeast Asia Hemophilia Gene Therapy Market Size and Forecast (2020-2031)
    • 8.3.7 Australia Hemophilia Gene Therapy Market Size and Forecast (2020-2031)

9 South America

  • 9.1 South America Hemophilia Gene Therapy Consumption Value by Type (2020-2031)
  • 9.2 South America Hemophilia Gene Therapy Consumption Value by Application (2020-2031)
  • 9.3 South America Hemophilia Gene Therapy Market Size by Country
    • 9.3.1 South America Hemophilia Gene Therapy Consumption Value by Country (2020-2031)
    • 9.3.2 Brazil Hemophilia Gene Therapy Market Size and Forecast (2020-2031)
    • 9.3.3 Argentina Hemophilia Gene Therapy Market Size and Forecast (2020-2031)

10 Middle East & Africa

  • 10.1 Middle East & Africa Hemophilia Gene Therapy Consumption Value by Type (2020-2031)
  • 10.2 Middle East & Africa Hemophilia Gene Therapy Consumption Value by Application (2020-2031)
  • 10.3 Middle East & Africa Hemophilia Gene Therapy Market Size by Country
    • 10.3.1 Middle East & Africa Hemophilia Gene Therapy Consumption Value by Country (2020-2031)
    • 10.3.2 Turkey Hemophilia Gene Therapy Market Size and Forecast (2020-2031)
    • 10.3.3 Saudi Arabia Hemophilia Gene Therapy Market Size and Forecast (2020-2031)
    • 10.3.4 UAE Hemophilia Gene Therapy Market Size and Forecast (2020-2031)

11 Market Dynamics

  • 11.1 Hemophilia Gene Therapy Market Drivers
  • 11.2 Hemophilia Gene Therapy Market Restraints
  • 11.3 Hemophilia Gene Therapy Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Hemophilia Gene Therapy Industry Chain
  • 12.2 Hemophilia Gene Therapy Upstream Analysis
  • 12.3 Hemophilia Gene Therapy Midstream Analysis
  • 12.4 Hemophilia Gene Therapy Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Hemophilia Gene Therapy market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
    Hemophilia is a rare bleeding disorder in which the blood does not clot normally. Hemophilia is a monogenic disease (a disease that is caused by a genetic defect in a single gene). There are two types of hemophilia caused by mutations in genes that encode protein factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most frequent forms of hemophilia affect males.
    Global Hemophilia Gene Therapy key players include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, etc.
    This report is a detailed and comprehensive analysis for global Hemophilia Gene Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Hemophilia Gene Therapy market size and forecasts, in consumption value ($ Million), 2020-2031
    Global Hemophilia Gene Therapy market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
    Global Hemophilia Gene Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
    Global Hemophilia Gene Therapy market shares of main players, in revenue ($ Million), 2020-2025
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Hemophilia Gene Therapy
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Hemophilia Gene Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Spark Therapeutics, Ultragenyx, Shire PLC, Sangamo Therapeutics, Bioverativ, BioMarin, uniQure, Freeline Therapeutics, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Hemophilia Gene Therapy market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Hemophilia A
    Hemophilia B
    Market segment by Application
    Hemophilia A Gene Therapy
    Hemophilia B Gene Therapy
    Market segment by players, this report covers
    Spark Therapeutics
    Ultragenyx
    Shire PLC
    Sangamo Therapeutics
    Bioverativ
    BioMarin
    uniQure
    Freeline Therapeutics
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Hemophilia Gene Therapy product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Hemophilia Gene Therapy, with revenue, gross margin, and global market share of Hemophilia Gene Therapy from 2020 to 2025.
    Chapter 3, the Hemophilia Gene Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Hemophilia Gene Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Hemophilia Gene Therapy.
    Chapter 13, to describe Hemophilia Gene Therapy research findings and conclusion.

    Buy now